Skip to content
Politically.com Search all
Menu

2026 · 1st Quarter (Jan 1 - Mar 31)

FULCRUM THERAPEUTICS

Filed by THE MCMANUS GROUP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
1st Quarter - Report
Posted
Apr 20, 2026
Income
$50,000.00
Expenses
Not reported
Filing UUID
aa2a21c5-f51a-4983-97f9-a85970c000e1
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Education and advocacy regarding sickle cell disease, including H.R. 1796/S. 735- Sickle Cell Disease and Other Heritable Blood Disorders, Research, Surveillance, Prevention, and Treatment Act of 2025. Priority review vouchers: Give Kids a Chance Act of 2025 (H.R. 1262/S.932) Issues related to FDA Accelerated Approval Pathways

Literal federal measure citations: H.R. 1796, S. 735, H.R. 1262, S.932

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.